

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
1	18/LO/1923	253458	A descriptive non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke attributable to nonvalvular atrial fibrillation	Range Agreed	40	50	Date Agreed	30/06/2021	43	43	30/06/2021	Recruitment finished	
2	19/NE/0260	265062	An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy	Number Agreed	5	5	Date Agreed	07/06/2021	5	5	30/04/2021	Recruitment finished	
3	19/EM/0111	262811	CRTH258C2302: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolicizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (RAVEN)	Number Agreed	4	4	Date Agreed	16/07/2021	4	4	27/05/2021	Recruitment finished	
4	19/NE/0247	259906	A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Fibrinogenolytic (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction	Range Agreed	5	10	Date Agreed	30/06/2021	4	4	30/06/2021	Recruitment finished	Study recruitment was impacted by COVID-19 and the study team was unable to meet the target of 5
5	19/SC/0209	263492	A multinational, multicentre, prospective non-interventional study to assess safety and effectiveness of opicapone plus standard of care in elderly patients with Parkinson's Disease	Range Agreed	2	6	Date Agreed	28/04/2021	2	2	22/04/2021	Recruitment finished	
6	20/SC/0031	275229	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis	Range Agreed	1	3	Date Agreed	30/06/2021	0	0	22/04/2021	Withdrawn by sponsor	Global recruitment ended prior to staff capacity issues being resolved at local site
7	20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting	Range Agreed	1	10	Date Agreed	07/04/2021	0	0	07/04/2021	Withdrawn by sponsor	After careful consideration, Gilead (Sponsor) made the decision to stop enrollment in study GS-US-540-9012. In light of recent advances, the primary unmet need for patients outside of the hospital setting is for convenient, effective therapies that can be easily administered at home.
8	20/NW/0177	1003027	Phase 3b Open-Label, Multicenter, Safety Study of BILB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205.	Range Agreed	1	2	Date Agreed	30/04/2021	1	1	30/04/2021	Recruitment finished	
9	20/WA/0203	281292	POLARx Cardiac Cryoablation system Post Market Clinical Follow-up study	Range Agreed	1	10	Date Agreed	30/06/2021	10	10	26/05/2021	Recruitment finished	
10	20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Number Agreed	200	200	Date Agreed	09/04/2021	207	207	09/04/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
11	21/NW/0125	294164	A RANDOMIZED, OBSERVER-BLIND, CONTROLLED, SUPERIORITY STUDY TO COMPARE THE IMMUNOGENICITY AGAINST COVID-19, OF VLA2001 VACCINE TO AZD1222 VACCINE, IN ADULTS	Range Agreed	120	200	Date Agreed	03/06/2021	134	134	03/06/2021	Recruitment finished	
12	19/LO/1753	269460	A phase 2, randomised, double-blind, placebo controlled study to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of SAR339375 for subcutaneous injection administered every week in patients with Alport Syndrome	Number Agreed	1	1	Date Agreed	31/05/2021	2	2	31/05/2021	Recruitment finished	
13	18/WM/0038	235048	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy.	Number Agreed	1	1	Date Agreed	11/06/2021	0	0	11/06/2021	Recruitment finished	Recruitment closed globally. However, study was very difficult to recruit to due to standard medication being already available
14	18/SW/0159	244565	An International, Prospective Registry Investigating the Natural History of Children with Achondroplasia	Range Agreed	5	10	Date Agreed	30/06/2023	5	5	09/08/2021	Recruitment finished	
15	18/SC/0305	246109	A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel Spartalizumab (PDR001) combinations in previously treated unresected or metastatic melanoma	Range Agreed	5	12	Date Agreed	05/07/2021	0	0	26/05/2021	Withdrawn by sponsor	Sponsor closed all arms of this study
16	17/EM/0192	223856	A Phase 2, 24-week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study, Followed by a 24-Week Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis	Range Agreed	1	3	Date Agreed	30/11/2021	3	3	23/07/2021	Recruitment finished	
17	19/NM/0442	262204	An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis	Number Agreed	2	2	Date Agreed	30/06/2021	2	2	30/06/2021	Recruitment finished	
18	18/LO/1937	249639	A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors	Range Agreed	1	3	Date Agreed	30/09/2021	2	2	10/06/2021	Recruitment finished	
19	19/EM/0300	267054	Effectiveness of an image analysing algorithm to diagnose non-melanoma skin cancers compared to gold standard histological determination.	Range Agreed	10	50	Date Agreed	30/07/2021	10	10	30/07/2021	Recruitment finished	
20	20/EE/0031	275993	Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke	Range Agreed	8	10	Date Agreed	02/08/2021	7	7	22/07/2021	Recruitment finished	Global target was hit earlier than expected and the sponsor closed the study to recruitment

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
21	20/NI/0111	283403	AT100-01: An AAV8 Neutralizing Antibody Seroprevalence Study in Subjects with Late Onset Pompe Disease	Number Agreed	5	5	Date Agreed	01/07/2021	5	5	01/07/2021	Recruitment finished	
22	20/EE/0170	1003070	Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction	Number Agreed	10	10	Date Agreed	31/07/2021	7	7	15/07/2021	Recruitment finished	Recruitment ended early nationally after global recruitment was met
23	20/LO/0828	279777	Master protocol of two randomized, double-blind, placebo controlled, multi center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment in patients naïve to omalizumab and in patients who are intolerant or incomplete responders to omalizumab	Number Agreed	1	1	Date Agreed	27/10/2021	0	0	30/09/2021	Withdrawn by sponsor	Due to the pandemic, the UK recruitment was sinificantly affected and sponsor closed the study earlier than expected
24	20/YH/0178	283168	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.	Number Agreed	4	4	Date Agreed	31/10/2021	0	0	03/09/2021	Withdrawn by sponsor	Recruitment finished early nationally
25	20/EM/0284	288568	A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chronic Hepatitis B Virus (B-Together)	Range Agreed	1	2	Date Agreed	31/10/2021	1	1	25/08/2021	Recruitment finished	
26	21/SC/0200	300677	A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults Ages 30 and Above to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2	Range Agreed	50	70	Date Agreed	07/09/2021	62	62	07/09/2021	Recruitment finished	
27	19/SW/0191	270987	Ross for Valve replacement in Adults(REVIVAL) Registry	Range Agreed	6	18	Date Agreed	31/07/2022	5	5	04/10/2021	Withdrawn by sponsor	Due to issues with recruitment and lack of demonstrable feasibility for the main trial, the sponsor came to the decision to close recruitment earlier than expected
28	18/WM/0039	236159	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433	Number Agreed	1	1	Date Agreed	01/01/2022	0	0	15/09/2021	Withdrawn by sponsor	No patients were found suitable to proceed to the extension study, which was closed by sponsor
29	18/LO/1125	247338	Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen	Range Agreed	3	8	Date Agreed	19/11/2021	6	6	19/11/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
30	17/NE/0058	219540	A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors	Number Agreed	4	4	Date Agreed	28/02/2023	7	7	31/12/2021	Recruitment finished	
31	13/YH/0317	141843	Vercise DBS Registry / version AB Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D) in adults	Range Agreed	1	10	Date Agreed	31/12/2021	9	9	31/12/2021	Recruitment finished	
32	18/NE/0023	230930	A Phase 3, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) The ARMOR Study	Range Agreed	20	204	Date Agreed	31/05/2021	203	203	31/05/2021	Recruitment finished	
33	19/NE/0357	271261	A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)	Range Agreed	1	5	Date Agreed	31/12/2021	1	1	15/12/2021	Recruitment finished	
34	18/LO/0122	238790	M19-164: A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to risankizumab.	Range Agreed	4	8	Date Agreed	18/12/2021	3	3	12/11/2021	Recruitment finished	Recruitment finished early nationally as global recruitment was met
35	19/NE/0328	270912	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA	Number Agreed	5	5	Date Agreed	31/10/2021	0	0	28/08/2021	Recruitment finished	The research team were unable to find people who met the strict eligibility criteria
36	20/LO/0453	1003010	A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19	Range Agreed	3	6	Date Agreed	30/11/2021	1	1	23/06/2021	Recruitment finished	Due to competitive recruitment the team did not meet their target
37	20/HRA/4788	288786	A Multicenter, non-interventional, prospective study to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis in daily practice (CIMREAL)	Range Agreed	11	18	Date Agreed	08/10/2021	5	5	01/10/2021	Recruitment finished	The study closed early nationally
38	19/NW/0555	269550	A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)	Range Agreed	2	5	Date Agreed	17/12/2021	2	2	17/12/2021	Recruitment finished	
39	20/NE/0058	275056		Range Agreed	1	3	Date Agreed	30/06/2023	3	3	16/11/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
40	18/SW/0130	246372	Prospective Evaluation of Thin-strut Biodegradable Polymer-coated Supraflex Sirolimus-Eluting Stents in an All-comers Patient Population (S-FLEX UK-II)	Range Agreed	50	100	Date Agreed	30/09/2021	73	73	30/09/2021	Recruitment finished	
41	20/HRA/5234	290965	A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19	Number Agreed	10	10	Date Agreed	01/12/2021	10	10	11/11/2021	Recruitment finished	
42	20/LO/0676	273137	Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)	Range Agreed	1	3	Date Agreed	31/12/2021	0	0	30/11/2021	Recruitment finished	Recruitment finished early nationally as global recruitment was met
43	20/LO/0731	279972	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis	Range Agreed	1	3	Date Agreed	30/11/2021	1	1	30/11/2021	Recruitment finished	
44	19/NE/0310	263546	A Phase IIb double-blind, randomised, placebo-controlled, multi-centre, confirmative three-way cross-over study on cognitive function with two doses of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNA ^{Leu} (UUR) m.3243A>G mutation	Range Agreed	6	10	Date Agreed	31/12/2021	6	6	31/12/2021	Recruitment finished	
45	20/LO/0963	281310	Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)	Number Agreed	6	6	Date Agreed	31/12/2021	0	0	31/12/2021	Recruitment finished	When the study opened the team were running with 2 consultants. Unfortunately one consultant became absent due to ill health throughout the study and the team were unable to screen patients due to these circumstances
46	20/LO/0181	275690	A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (Pvd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma	Range Agreed	2	4	Date Agreed	31/10/2021	3	3	31/10/2021	Recruitment finished	
47	21/YH/0071	295903	Phase 2/3, Placebo-Controlled, Randomized, Observer-Blinded, Study to Evaluate to the Safety, Tolerability and Immunogenicity of SARS-CoV-2 RNA Vaccine Candidate (BNT162b2) against COVID-19 IN Healthy Pregnant Women 18 years of Age and Older.	Range Agreed	1	3	Date Agreed	31/10/2021	1	1	25/10/2021	Recruitment finished	
48	19/SC/0599	270649	A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumours	Number Agreed	5	5	Date Agreed	15/12/2023	0	0	06/12/2021	Recruitment finished	Global recruitment finished early. The team at Newcastle were only offered one slot by sponsor and the patient screen failed

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
49	21/NS/0037	292756	A prospective observational study to evaluate the clinical outcomes and burden of disease of PD patients with motor fluctuations not adequately controlled by current PD medications.	Number Agreed	10	10	Date Agreed	31/12/2021	7	7	13/12/2021	Recruitment finished	This study was difficult to recruit to as one of the main issues were visits coincided with normal outpatient visits and, visit windows were often cancelled because of COVID
50	21/NW/0260	299431	A Multicenter Retrospective Study of the HARMONIC Focus (+) Shears in Adult Urologic and Gynecologic Procedures and Pediatric Procedures	Number Agreed	100	100	Date Agreed	28/02/2022	103	103	01/11/2021	Recruitment finished	
51	19/LO/0043	255663	A long-term extension trial of the Phase III lipid-lowering trials to assess the effect of long-term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C	Number Agreed	3	3	Date Agreed	01/11/2021	3	3	01/11/2021	Recruitment finished	
52	19/ES/0126	271121	A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations	Number Agreed	1	1	Date Agreed	09/01/2022	1	1	09/01/2022	Recruitment finished	
53	19/LO/0062	255909	A StUdy eVALUatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients	Number Agreed	2	2	Date Agreed	30/09/2022	2	2	24/01/2022	Recruitment finished	
54	21/WA/0008	283679	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL OR HEMIRETINAL VEIN OCCLUSION	Range Agreed	3	8	Date Agreed	01/09/2022	9	9	19/01/2022	Recruitment finished	
55	18/NE/0003	236908	GCT 1029-01- First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors	Number Agreed	10	10	Date Agreed	31/10/2021	6	6	31/10/2021	Recruitment finished	The study study was closed earlier than expected as the drug had unexpected toxicity, so the team could not give an effective dose
56	18/LO/2045	252053	The 'Radiance II' Pivotal Study. A study of the ReCor Medical Paradise System in Stage II Hypertension.	Number Agreed	2	2	Date Agreed	25/03/2022	2	2	25/03/2022	Recruitment finished	
57	19/ES/0022	258326	Prospective, Longitudinal Study of the Natural History and Functional Status of Patients with Limb-Girdle Muscular Dystrophy 2I	Number Agreed	8	8	Date Agreed	05/01/2022	8	8	05/01/2022	Recruitment finished	
58	19/NW/0317	262846	A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbuphine ER Tablets for the Treatment of Cough	Range Agreed	3	5	Date Agreed	11/03/2022	2	2	11/03/2022	Recruitment finished	Third person was consented but withdrew after randomisation
59	19/EM/0189	264788	A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	Range Agreed	3	6	Date Agreed	02/09/2023	0	0	06/10/2021	Withdrawn by sponsor	Study closed to recruitment during COVID
60	19/NE/0361	272352	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjogren's Syndrome (SS)	Range Agreed	1	4	Date Agreed	31/12/2022	1	1	12/01/2022	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
61	20/NW/0310	267092	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease (CVD).	Range Agreed	16	26	Date Agreed	30/04/2022	16	16	08/03/2022	Recruitment finished	
62	19/LO/1401	269001	Multi-country prospective observational cohort study of patients with moderate to severe chronic plaque psoriasis (VALUE)	Number Agreed	10	10	Date Agreed	31/03/2022	9	9	31/03/2022	Recruitment finished	There were no further participants identified as eligible from the Dermatology Outpatient Biologics Clinic within the recruitment closure deadline.
63	20/NW/0260	1003209	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation	Range Agreed	2	4	Date Agreed	30/04/2023	1	1	20/12/2021	Recruitment finished	Sponsor closed study early due to filling all of the slots Globally
64	20/PR/0005	281137	PEARL: Fremanezumab effectiveness in chronic or episodic migraine.	Number Agreed	16	16	Date Agreed	31/03/2022	16	16	31/03/2022	Recruitment finished	
65	21/NE/0097	293215	Management strategies and clinical outcomes associated with cytomegalovirus (CMV) disease prevention in renal transplant patients in the UK (MAESTRO).	Number Agreed	20	20	Date Agreed	25/02/2022	23	23	03/02/2022	Recruitment finished	
66	20/ES/0034	276977	A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours	Number Agreed	5	5	Date Agreed	01/07/2022	0	0	26/01/2022	Withdrawn by sponsor	Study closed early by sponsor because the drug was found to be too toxic, and the study halted on safety grounds before the research team were able to recruit to a slot
67	21/NE/0128	289134	A Phase IIIb, open-label, single-arm, single-dose, multicenter study to evaluate the safety, tolerability and efficacy of gene replacement therapy with intravenous OAV101 (AVXS-101) in pediatric patients with spinal muscular atrophy (SMA)	Range Agreed	1	3	Date Agreed	30/06/2022	2	2	08/02/2022	Recruitment finished	